Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)
6,044.00
-1.00 (-0.02%)
Apr 17, 2026, 3:30 PM JST
TYO:4530 Balance Sheet
Financials in millions JPY. Fiscal year is March - February.
Millions JPY. Fiscal year is Mar - Feb.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
Cash & Equivalents | 108,859 | 114,518 | 112,459 | 122,154 | 129,290 |
Short-Term Investments | 9,779 | 14,598 | 12,862 | 14,714 | 13,141 |
Cash & Short-Term Investments | 118,638 | 129,116 | 125,321 | 136,868 | 142,431 |
Cash Growth | -8.12% | 3.03% | -8.44% | -3.91% | 4.73% |
Receivables | 56,322 | 46,879 | 42,983 | 39,753 | 38,112 |
Inventory | 25,916 | 22,391 | 21,176 | 18,922 | 16,412 |
Other Current Assets | 5,033 | 5,402 | 4,542 | 3,631 | 3,221 |
Total Current Assets | 205,909 | 203,788 | 194,022 | 199,174 | 200,176 |
Property, Plant & Equipment | 60,519 | 59,899 | 49,462 | 43,209 | 39,069 |
Long-Term Investments | 92,996 | 71,494 | 76,813 | 69,244 | 61,133 |
Goodwill | 1,143 | 1,294 | 1,444 | - | - |
Other Intangible Assets | 4,237 | 4,680 | 5,387 | 946 | 1,326 |
Long-Term Deferred Tax Assets | 2,357 | 1,911 | 1,649 | 1,342 | 1,153 |
Other Long-Term Assets | 1 | 2 | 2 | 2 | 1 |
Total Assets | 367,162 | 343,068 | 328,779 | 313,917 | 302,858 |
Accounts Payable | 17,216 | 14,115 | 16,263 | 14,918 | 13,225 |
Accrued Expenses | 2,422 | 2,213 | 1,831 | 1,340 | 1,363 |
Short-Term Debt | 907 | 1,065 | 1,071 | 1,071 | 1,071 |
Current Portion of Leases | 344 | 409 | 350 | 327 | 301 |
Current Income Taxes Payable | 11,847 | 11,779 | 9,861 | 8,587 | 9,623 |
Other Current Liabilities | 17,682 | 17,645 | 16,562 | 16,335 | 6,577 |
Total Current Liabilities | 50,418 | 47,226 | 45,938 | 42,578 | 32,160 |
Long-Term Debt | - | 1,694 | 76 | 147 | 219 |
Long-Term Leases | 1,124 | 688 | 603 | 750 | 869 |
Pension & Post-Retirement Benefits | 7,575 | 7,819 | 8,598 | 8,408 | 8,216 |
Long-Term Deferred Tax Liabilities | 11,581 | 4,304 | 4,518 | 1,813 | 4,170 |
Other Long-Term Liabilities | 1,771 | 1,932 | 1,967 | 1,815 | 2,339 |
Total Liabilities | 72,469 | 63,663 | 61,700 | 55,511 | 47,973 |
Common Stock | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 |
Additional Paid-In Capital | 2,356 | 2,361 | 2,361 | 2,361 | 2,356 |
Retained Earnings | 230,653 | 257,881 | 242,578 | 235,569 | 236,192 |
Treasury Stock | -19,127 | -47,550 | -36,993 | -27,196 | -19,527 |
Comprehensive Income & Other | 69,464 | 55,659 | 48,455 | 37,157 | 25,674 |
Total Common Equity | 291,819 | 276,824 | 264,874 | 256,364 | 253,168 |
Minority Interest | 2,874 | 2,581 | 2,205 | 2,042 | 1,717 |
Shareholders' Equity | 294,693 | 279,405 | 267,079 | 258,406 | 254,885 |
Total Liabilities & Equity | 367,162 | 343,068 | 328,779 | 313,917 | 302,858 |
Total Debt | 2,375 | 3,856 | 2,100 | 2,295 | 2,460 |
Net Cash (Debt) | 116,263 | 125,260 | 123,221 | 134,573 | 139,971 |
Net Cash Growth | -7.18% | 1.65% | -8.44% | -3.86% | 4.15% |
Net Cash Per Share | 1627.51 | 1699.18 | 1600.21 | 1694.75 | 1722.30 |
Filing Date Shares Outstanding | 70.4 | 72.96 | 75.74 | 77.77 | 79.74 |
Total Common Shares Outstanding | 70.4 | 72.96 | 75.74 | 77.74 | 79.74 |
Working Capital | 155,491 | 156,562 | 148,084 | 156,596 | 168,016 |
Book Value Per Share | 4145.07 | 3794.04 | 3497.00 | 3297.53 | 3175.01 |
Tangible Book Value | 286,439 | 270,850 | 258,043 | 255,418 | 251,842 |
Tangible Book Value Per Share | 4068.65 | 3712.17 | 3406.82 | 3285.36 | 3158.38 |
Updated Feb 28, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.